Vivos Therapeutics Enters Material Agreement, Discloses Equity Sales
Ticker: VVOS · Form: 8-K · Filed: May 23, 2025 · CIK: 1716166
| Field | Detail |
|---|---|
| Company | Vivos Therapeutics, Inc. (VVOS) |
| Form Type | 8-K |
| Filed Date | May 23, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
Vivos Therapeutics signed a new deal and sold stock, creating debt and equity sales.
AI Summary
On May 21, 2025, Vivos Therapeutics, Inc. entered into a material definitive agreement, which also created a direct financial obligation for the company. The filing also disclosed unregistered sales of equity securities. Specific details regarding the agreement and the financial obligation were not provided in this summary.
Why It Matters
This filing indicates Vivos Therapeutics has entered into a significant new agreement and has sold equity, which could impact its financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing mentions a material definitive agreement and direct financial obligations, which inherently carry financial risk, alongside unregistered equity sales that can dilute existing shareholders.
Key Players & Entities
- Vivos Therapeutics, Inc. (company) — Registrant
- May 21, 2025 (date) — Date of earliest event reported
- May 23, 2025 (date) — Date of Report
FAQ
What is the nature of the material definitive agreement entered into by Vivos Therapeutics?
The filing does not specify the details of the material definitive agreement.
What is the direct financial obligation created by the agreement?
The filing states a direct financial obligation was created but does not provide specific financial details.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 21, 2025.
What type of securities were sold under the unregistered sales of equity securities?
The filing mentions unregistered sales of equity securities but does not specify the type.
What is Vivos Therapeutics' state of incorporation?
Vivos Therapeutics, Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 23, 2025 regarding Vivos Therapeutics, Inc. (VVOS).